Related Experiment Video
Updated: May 15, 2026
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
Preemptive cardioprotection with a small molecule in rodents that suppresses genes predictive of heart failure
Yue Li1, Matthew V Andrews2, David T Humphreys3,4
1Vascular Biology and Translational Research, School of Biomedical Sciences, Department of Pathology, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Insights
BT2, a novel cardioprotective agent, significantly reduced heart damage and improved cardiac function in rats by preventing inflammation and fibrosis. This offers a promising strategy for patients undergoing percutaneous coronary intervention.
Area of Science:
- Cardiovascular Research
- Molecular Cardiology
- Pharmacology
Background:
- Ischemic heart disease remains a major global health concern.
- Percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) can cause reperfusion injury, worsening myocardial damage and leading to heart failure (HF).
- There is a need for preemptive cardioprotective strategies to mitigate PCI-related injury.
Purpose of the Study:
- To investigate the efficacy of BT2, a small-molecule inhibitor of MAPK kinase/extracellular signal-regulated kinase, as a preemptive cardioprotective agent.
- To evaluate BT2's impact on myocardial infarct size, cardiac function, and cardiac remodeling post-ischemia-reperfusion injury.
- To explore BT2's molecular mechanisms, including its effects on inflammatory and fibrotic gene expression.
Main Methods:
- Administration of BT2 in a rat model of myocardial ischemia-reperfusion injury, 24 hours before and during ischemia.
- Assessment of infarct size and cardiac function at 24 hours and 2 weeks post-reperfusion.
- Utilized single nucleus RNA sequencing (snRNA-seq) and bulk RNA-seq to analyze gene expression changes in cardiac tissue.
- Evaluated macrophage and neutrophil infiltration and expression of HF-predictive genes.
Main Results:
- BT2 administration reduced infarct size by approximately 70% and preserved cardiac function.
- BT2 prevented adverse left ventricular remodeling and cardiac scarring.
- Gene expression analysis revealed BT2 modulated genes involved in inflammation, fibrosis, and matrix production, particularly in macrophages and myofibroblasts.
- BT2 suppressed macrophage and neutrophil infiltration and reduced expression of HF-associated genes.
Conclusions:
- Preemptive administration of BT2 effectively prevents myocardial ischemia-reperfusion injury in rats.
- BT2 improves cardiac function, reduces fibrosis, and favorably modulates key molecular pathways linked to heart failure.
- This strategy holds potential for clinical evaluation in high-risk ACS patients or those undergoing elective PCI.
Abstract:
Ischemic heart disease is a leading cause of death worldwide. While percutaneous coronary intervention (PCI) restores blood flow in acute coronary syndrome (ACS), reperfusion injury exacerbates myocardial damage, contributing to heart failure (HF). Preemptive administration of a cardioprotective agent could help counter the imminent proinflammatory insult of PCI and reperfusion. Administering BT2, a small-molecule MAPK kinase/extracellular signal-regulated kinase inhibitor, 24 hours before and during ischemia in rats before reperfusion reduced infarct size by ~70% and preserved cardiac function 24 hours and 2 weeks postinjury. BT2 prevented adverse left ventricular remodeling and scarring. Single nucleus RNA sequencing (snRNA-seq) and bulk RNA-seq revealed that BT2 modulated genes associated with inflammation, fibrosis, and matrix production, especially within macrophages and myofibroblasts. BT2 suppressed macrophage and neutrophil infiltration. BT2 reduced the expression of genes in rodent hearts predictive of HF in patients with ACS, including many encoding cytokines, inflammasome components, and damage-associated molecular patterns. BT2 is a small molecule that can prevent myocardial ischemia-reperfusion injury, improve heart function, reduce cardiac fibrosis, and favorably modulate multiple key genes and biological processes in rats prognostic of HF when delivered before reperfusion. This strategy could be evaluated with high-risk unstable angina/non-ST-segment elevation myocardial infarction patients or those having an elective PCI.
